Medical Robotic Innovations Featured at the LSI 2021 Emerging Medtech Summit
Keynote Speakers and Final Roster of Selected Presenting Companies Announced
News provided by
Share this article
Share this article
LOS ANGELES, April 12, 2021 /PRNewswire/ Medical robotic innovations will be one of the hot topics at the LSI 2021 Emerging Medtech Summit that will be held May 11-13 at The Ritz-Carlton Laguna Niguel Hotel in Dana Point, California. More than 450 attendees are expected at this year s summit, with over 160 medtech startup CEOs and over 100 investors confirmed, including venture capital funds, private equity funds, SPACs and strategic investors.
(PRNewsfoto/Life Science Intelligence) We re excited to have such a strong group of innovators presenting their developments in this hot space of robotics. The CEOs of these companies are drawing quite a bit of attention, says Scott Pantel, CEO of LSI. It is fascinating to track which strategics and investors are focusing in
Tyler Jacks, Ph.D., after 19 years. The director role will be taken over by
Matthew Vander Heiden, M.D., Ph.D., a professor of biology at MIT and a medical oncologist at Dana-Farber Cancer Institute. He became a member of the Koch Institute in 2010 and took over for Jacks on Thursday, MIT said. Jacks will continue to lead the Bridge Project, which unites bioegnineers, cancer scientists and clinical oncologists from the Koch Institute and the Dana-Farber/Harvard Cancer Center.
> Atara Biotherapeutics ushered
Amie Krause into the role of senior vice president and chief people officer April 2. Since joining the company, Krause has been the driving force behind Atara’s human people department, advocating for employees across the organization. She doubles as a founding leader of Atara’s Women’s Alliance and is part of the Healthcare Businesswomen’s Association. Before signing on with Atara, Krause held several top human resources roles at Amgen, including HR lead for the
Arix Bioscience PLC: Artios announces collaboration with Novartis to create next generation DDR cancer therapies
DJ Artios announces collaboration with Novartis to create next generation DDR cancer therapies
Arix Bioscience PLC (ARIX)
Artios announces collaboration with Novartis to create next generation DDR cancer therapies
07-Apr-2021 / 07:00 GMT/BST
Dissemination of a Regulatory Announcement, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
=
Arix Bioscience plc
Artios announces collaboration with Novartis to create next generation DDR cancer therapies - Artios to receive USD20 million up-front payment in addition to near term research funding to support the
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Artios Pharma Announces Collaboration with Novartis to Create Next Generation DDR Cancer Therapies
Artios Pharma, Inc.April 7, 2021 GMT
Novartis to leverage Artios’ discovery platform to identify DDR targets for use with Novartis’ proprietary radioligand therapies.
Artios to receive US$20 million up-front payment in addition to near term research funding to support the collaboration.
Artios eligible to receive up to $1.3 billion in discovery, development, regulatory and sales-based milestones in addition to royalty payments.
CAMBRIDGE, United Kingdom and NEW YORK, April 07, 2021 (GLOBE NEWSWIRE) Artios Pharma Limited (Artios), a leading DNA Damage Response (DDR) company exploiting synthetic lethality to develop a broad pipeline of precision medicines for the treatment of cancer, today announced a global research collaboration with Novartis to discover and validate next generatio